Prestige Forecasts Under $20 Million In Clear Eyes Sales As Output Falters, Cuts Outlook

The CEO called Clear Eyes "the other 1.5%" of sales, but zero safety stock and production problems forced a lower full-year forecast.

Share
Prestige Forecasts Under $20 Million In Clear Eyes Sales As Output Falters, Cuts Outlook

Prestige Consumer Healthcare, which sells branded consumer health products including the Clear Eyes eye care line, is now forecasting less than $20 million in Clear Eyes sales for the full year, CEO Ron Lombardi said on the company's earnings call Thursday. Production faltered at its Pillar5 site, and the company lowered its fiscal 2027 outlook.

Zero safety stock, immediate hit

Lombardi said in prepared remarks that production volatility began in late September and continued into October. With zero safety stock, the impact was felt at once, and he said fixes take time because of the nature of sterile manufacturing.

Full-year revenue guidance is now $1,280 million to $1,290 million, and adjusted earnings per share $4.48 to $4.55. For the third quarter, the company expects revenue of about $328 million and adjusted EPS of $1.05. Lombardi said the revenue cut is primarily due to supply availability and does not reflect a change in the broader portfolio, which he said equates to about 2% organic growth excluding Clear Eyes.

Prestige shares fell 16.67% to $44.40 in Thursday trading, for a market value of $2.5 billion.

"The other 98.5%"

Answering an analyst at Canaccord Genuity, Lombardi said he was "delighted to talk about the other 98.5% of our sales" and handed Clear Eyes, "the other 1.5%," to CFO and COO Christine Sacco.

Sacco said third-quarter Clear Eyes product has already been produced and that the fourth-quarter forecast assumes output at levels reached before the October shutdown. Third quarter should be the brand's lowest of the year, she said, partly because it laps the highest sales level of the prior year.

A Jefferies analyst pressed on what is taking longer and on visibility into fiscal 2028. Lombardi said the opportunity is unchanged and a new management team is in place, "off of this low base."

Why Prestige bought Pillar5

Prestige bought Pillar5 last December. Lombardi said ownership gives vertical integration and direct control to support long-term, high-volume demand, and that regulators have inspected the site several times with favorable conclusions. Site management changes are less than 60 days old.

He said shortages are industry-wide, as tighter global inspections have pulled foreign-based suppliers out of supply. Clear Eyes sold nearly 50 million bottles a year at its peak, he said, in a category of roughly $2 billion at retail.

Elsewhere, second-quarter revenue rose 22.7% to $336.3 million on the Breathe Right and Lacorium acquisitions, and adjusted EPS was $1.13. Net debt was about $2.1 billion, and Prestige plans to put free cash flow toward debt reduction for the rest of the fiscal year.

Sacco said the aim for fiscal 2028 is a more "predictable and repeatable" output from Clear Eyes production lines.

Sources

More on Prestige Consumer Healthcare

All Prestige Consumer Healthcare (PBH) coverage →